Skip Navigation

Adalvo announces dossier submission for Eribulin solution for injection

12 August 2022

We are pleased to announce that our dossier submission for Eribulin solution for injection, 0.44mg/ml has been completed.

Our product has been developed based on the reference brand Halaven and is indicated in the treatment of Liposarcoma and Metastatic breast carcinoma. The product sold at $360mio globally in 2021, according to IQVIA.

Eribulin is a synthetic analogue of halichondrin B, and due to its complex structure, the synthetic process consists of 73 difficult steps which requires state of art technology to be executed. Moreover, being a molecule sensitive to light, humidity and heat, development of a stable finished product is challenging.

Our progress on this product further enhances our capabilities and due to its challenging nature, showcases our ability to bring complex products to our partners, with a competitive approach.

Disclaimer: Eribulin, which is subject to patent protection is currently not offered or made available in countries where patents are in force.